Transatlantic Group to Discuss European View of Plant-Made Pharmaceuticals
International Academy of Life Sciences to present at cPMP 2005.
Montreal, Canada (PRWEB via PR Web
Direct) January 25, 2005 –- Members of the International Academy of Life
Sciences will discuss the risks and opportunities the plant-made pharmaceuticals
industry faces in Europe during an upcoming conference.
The conference, cPMP 2005, to be held Jan. 30-Feb. 2 in Montreal, will bring
together some 40 PMP companies (30 presenting) and hundreds of participants for
a three-day session (four if you count the opening cocktail) that will look at
plant-factories from perspectives including business, drug development,
regulatory, science and public-perception.
Among the
participants in a panel discussion on stakeholders related to PMPs will be Dr.
Hilmar Stolte, IALS president and a professor at Hannover Medical School in
Germany.
“While the science of PMPs is quite advanced in Europe, the
application of research and development of products is much more advanced in
North America. However, our experience is that the potential is there for the
European public to receive this technology positively,” Stolte said.
The
International Academy of Life Sciences hosts the PlantPharma.org online
community, which is dedicated to a scientifically based, medically oriented
discussion on plant-made pharmaceuticals. IALS is a global network of
universities, medical schools, and related institutions that are dedicated to
education, training and research in key issues associated with the life
sciences.
On hand at the cPMP conference will be leading corporations
including Amgen, Baxter Bioscience, Centocor, Novartis and Wyeth BioPharma.
Companies presenting their protein-production platform, products or enabling
technologies include Grand Hosts Bayer CropScience (Germany), Dow AgroSciences
(USA), Nexgen (Korea), and Syngenta (Switzerland), along with Hosts that include
Chlorogen, Fraunhofer, SemBioSys, Medicago and Icon.
Plant-made pharmaceuticals are gaining increasing attention for their
potential to aid in the production of therapeutic proteins to treat diseases
such as cancer, HIV, heart disease, diabetes, Alzheimer’s disease, arthritis and
many more.
Using plants as the vehicle for pharmaceutical production
offers a variety of potential advantages, including fast and flexible supply to
meet patient needs, lower capital investments than current methods and the
ability to produce “difficult” proteins that are otherwise unavailable to the
health professionals..
For more information or to register for the
conference visit http://www.cpmp2005.org. For more information on IALS and
PlantPharma visit http://www.plantpharma.org.
Contact:
Sarah
Fuhrmann
877-835-8362
# # #
Source : http://www.prweb.com/releases/2005/1/prweb201511.htm